{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:17:41Z","timestamp":1707524261854},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,10]]},"DOI":"10.7759\/cureus.15568","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T15:35:58Z","timestamp":1623339358000},"source":"Crossref","is-referenced-by-count":0,"title":["Interferon-Induced Crohn\u2019s Disease: An Unusual Side Effect of Interferon Therapy in a Patient With Chronic Hepatitis C Virus Infection"],"prefix":"10.7759","author":[{"given":"Omer","family":"Basar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Dailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Dailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veysel","family":"Tahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebubekir","family":"Daglilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side effects of interferon-alpha therapy","volume":"27","author":"Sleijfer S","year":"2005","unstructured":"Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005, 27:423-31. 10.1007\/s11096-005-1319-7","journal-title":"Pharm World Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1995-7645(14)60193-0","article-title":"Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: treatment response, side effects and future prospective","volume":"8","author":"Waheed Y","year":"2015","unstructured":"Waheed Y. Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: treatment response, side effects and future prospective. Asian Pac J Trop Med. 2015, 8:85-89. 10.1016\/S1995-7645(14)60193-0","journal-title":"Asian Pac J Trop Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i31.4233","article-title":"Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report","volume":"18","author":"Baik SJ","year":"2012","unstructured":"Baik SJ, Kim TH, Yoo K, Moon IH, Cho MS. Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report. World J Gastroenterol. 2012, 18:4233-6. 10.3748\/wjg.v18.i31.4233","journal-title":"World J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21396","article-title":"Ulcerative colitis triggered by pegylated interferon alone therapy for chronic hepatitis C","volume":"17","author":"Alt\u0131nbas A","year":"2011","unstructured":"Alt\u0131nbas A, Koybas\u0131oglu F, Aktas E, Y\u0131lmaz B, Coban S. Ulcerative colitis triggered by pegylated interferon alone therapy for chronic hepatitis C. Inflamm Bowel Dis. 2011, 17:1050. 10.1002\/ibd.21396","journal-title":"Inflamm Bowel Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20152","article-title":"Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C","volume":"13","author":"Tursi A","year":"2007","unstructured":"Tursi A. Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C. Inflamm Bowel Dis. 2007, 13:1189-90. 10.1002\/ibd.20152","journal-title":"Inflamm Bowel Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0399-8320(05)80736-5","article-title":"Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C","volume":"29","author":"Khalil A","year":"2005","unstructured":"Khalil A, Lucidarme D, Desurmont P, Hamdan-Khalil R, Filoche B. Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C. Gastroenterol Clin Biol. 2005, 29:193-6. 10.1016\/s0399-8320(05)80736-5","journal-title":"Gastroenterol Clin Biol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2013.10.003","article-title":"Decoding the complexity of type I interferon to treat persistent viral infections","volume":"21","author":"Wilson EB","year":"2013","unstructured":"Wilson EB, Brooks DG. Decoding the complexity of type I interferon to treat persistent viral infections. Trends Microbiol. 2013, 21:634-40. 10.1016\/j.tim.2013.10.003","journal-title":"Trends Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i2.123","article-title":"Ribavirin: past, present and future","volume":"8","author":"Loustaud-Ratti V","year":"2016","unstructured":"Loustaud-Ratti V, Debette-Gratien M, Jacques J, et al.. Ribavirin: past, present and future. World J Hepatol. 2016, 8:123-30. 10.4254\/wjh.v8.i2.123","journal-title":"World J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05398.x","article-title":"Ribavirin in the treatment of chronic hepatitis C","volume":"23","author":"Martin P","year":"2008","unstructured":"Martin P, Jensen DM. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 2008, 23:844-55. 10.1111\/j.1440-1746.2008.05398.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang YZ","year":"2014","unstructured":"Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014, 20:91-9. 10.3748\/wjg.v20.i1.91","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200111000-00002","article-title":"Hepatitis B and C virus infection in Crohn's disease","volume":"7","author":"Biancone L","year":"2001","unstructured":"Biancone L, Pavia M, Del Vecchio Blanco G, et al.. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis. 2001, 7:287-94. 10.1097\/00054725-200111000-00002","journal-title":"Inflamm Bowel Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.105197","article-title":"A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin","volume":"55","author":"Watanabe T","year":"2006","unstructured":"Watanabe T, Inoue M, Harada K, et al.. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin. Gut. 2006, 55:1682-3. 10.1136\/gut.2006.105197","journal-title":"Gut"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.120","article-title":"Development of pouchitis with combination therapy with peg-interferon alpha-2b and ribavirin for chronic hepatitis C in a patient with ulcerative colitis who underwent pouch surgery","volume":"104","author":"Morimoto K","year":"2009","unstructured":"Morimoto K, Yamagami H, Hosomi S, et al.. Development of pouchitis with combination therapy with peg-interferon alpha-2b and ribavirin for chronic hepatitis C in a patient with ulcerative colitis who underwent pouch surgery. Am J Gastroenterol. 2009, 104:1609-10. 10.1038\/ajg.2009.120","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.12.1728","article-title":"A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis","volume":"52","author":"Tilg H","year":"2003","unstructured":"Tilg H, Vogelsang H, Ludwiczek O, et al.. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut. 2003, 52:1728-33. 10.1136\/gut.52.12.1728","journal-title":"Gut"},{"key":"ref15","article-title":"Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis","volume":"7","author":"S\u00fcmer N","year":"1995","unstructured":"S\u00fcmer N, Palabiyiko\u011flu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol. 1995, 7:597-602.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.07.014","article-title":"Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease","volume":"11","author":"Allen AM","year":"2013","unstructured":"Allen AM, Kim WR, Larson J, Loftus EV Jr. Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013, 11:1655-60.e1. 10.1016\/j.cgh.2013.07.014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref17","article-title":"Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease)","volume":"45","author":"Ruther U","year":"1998","unstructured":"Ruther U, Nunnensiek C, Muller HA, Bader H, May U, Jipp P. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). Hepatogastroenterology. 1998, 45:691-9.","journal-title":"Hepatogastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2010.03.001","article-title":"Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature","volume":"4","author":"Katsanos KH","year":"2010","unstructured":"Katsanos KH, Tsianos VE, Zois CD, et al.. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. J Crohns Colitis. 2010, 4:450-65. 10.1016\/j.crohns.2010.03.001","journal-title":"J Crohns Colitis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03779.x","article-title":"Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C","volume":"28","author":"Scherzer TM","year":"2008","unstructured":"Scherzer TM, Staufer K, Novacek G, et al.. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. Aliment Pharmacol Ther. 2008, 28:742-8. 10.1111\/j.1365-2036.2008.03779.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/53189-interferon-induced-crohns-disease-an-unusual-side-effect-of-interferon-therapy-in-a-patient-with-chronic-hepatitis-c-virus-infection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:24:43Z","timestamp":1707506683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/53189-interferon-induced-crohns-disease-an-unusual-side-effect-of-interferon-therapy-in-a-patient-with-chronic-hepatitis-c-virus-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.15568","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,10]]}}}